Comparison of CD4(+) T-cell subset distribution in chronically infected HIV(+) patients with various CD4 nadir counts. 2010

Keiko Sakai, and Hiroyuki Gatanaga, and Hiroshi Takata, and Shinichi Oka, and Masafumi Takiguchi
Division of Viral Immunology, Center for AIDS Research, Kumamoto University, 2-2-1 Honjo, Kumamoto-shi, Kumamoto-ken 860-0811, Japan.

Infection with HIV-1 causes CD4(+) T-cell dysfunction, including unresponsiveness to antigenic stimuli. To understand the mechanism of virally induced T-cell dysfunction, we investigated changes occurred in functional CD4(+) T-cell subsets in the peripheral CD4(+) T-cell pool in chronically infected aviremic individuals treated with antiretroviral therapy. We phenotypically defined CD4(+) T-cell subsets by surface markers and determined the frequency of each subset by flow cytometry. A substantially low naïve and elevated effector subsets were observed in chronically infected patients with nadir CD4 counts <100 cells/microl. The skewed distribution persisted in these patients even after their CD4 counts increased, and the subset imbalance was still observed in all four subsets after years of successful antiretroviral therapy. They also showed a limited recovery of CD4(+) T-cell counts compared to those who maintained at least 250 CD4(+) T cells/microl after 3-11 years of successful treatment since CD4 nadir time points. The difference was pronounced in the absolute numbers of naïve and T(EM) cells. Our results suggested a significant and prolonged impact of nadir CD4 counts on the balanced distribution of the functional CD4(+) T-cell subsets and may explain partially why antiretroviral therapy needs to be initiated while patients' CD4 counts remain relatively high.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015496 CD4-Positive T-Lymphocytes A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. T4 Cells,T4 Lymphocytes,CD4-Positive Lymphocytes,CD4 Positive T Lymphocytes,CD4-Positive Lymphocyte,CD4-Positive T-Lymphocyte,Lymphocyte, CD4-Positive,Lymphocytes, CD4-Positive,T-Lymphocyte, CD4-Positive,T-Lymphocytes, CD4-Positive,T4 Cell,T4 Lymphocyte
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016176 T-Lymphocyte Subsets A classification of T-lymphocytes, especially into helper/inducer, suppressor/effector, and cytotoxic subsets, based on structurally or functionally different populations of cells. T-Cell Subset,T-Cell Subsets,T-Lymphocyte Subset,Subset, T-Cell,Subset, T-Lymphocyte,Subsets, T-Cell,Subsets, T-Lymphocyte,T Cell Subset,T Cell Subsets,T Lymphocyte Subset,T Lymphocyte Subsets

Related Publications

Keiko Sakai, and Hiroyuki Gatanaga, and Hiroshi Takata, and Shinichi Oka, and Masafumi Takiguchi
January 2019, Mucosal immunology,
Keiko Sakai, and Hiroyuki Gatanaga, and Hiroshi Takata, and Shinichi Oka, and Masafumi Takiguchi
July 2010, AIDS (London, England),
Keiko Sakai, and Hiroyuki Gatanaga, and Hiroshi Takata, and Shinichi Oka, and Masafumi Takiguchi
October 2008, AIDS research and human retroviruses,
Keiko Sakai, and Hiroyuki Gatanaga, and Hiroshi Takata, and Shinichi Oka, and Masafumi Takiguchi
March 2021, The Journal of clinical investigation,
Keiko Sakai, and Hiroyuki Gatanaga, and Hiroshi Takata, and Shinichi Oka, and Masafumi Takiguchi
January 1984, Lancet (London, England),
Keiko Sakai, and Hiroyuki Gatanaga, and Hiroshi Takata, and Shinichi Oka, and Masafumi Takiguchi
August 2022, International journal of clinical oncology,
Keiko Sakai, and Hiroyuki Gatanaga, and Hiroshi Takata, and Shinichi Oka, and Masafumi Takiguchi
December 2008, Journal of acquired immune deficiency syndromes (1999),
Keiko Sakai, and Hiroyuki Gatanaga, and Hiroshi Takata, and Shinichi Oka, and Masafumi Takiguchi
September 2008, Viral immunology,
Keiko Sakai, and Hiroyuki Gatanaga, and Hiroshi Takata, and Shinichi Oka, and Masafumi Takiguchi
January 1999, The New England journal of medicine,
Keiko Sakai, and Hiroyuki Gatanaga, and Hiroshi Takata, and Shinichi Oka, and Masafumi Takiguchi
January 2007, AIDS (London, England),
Copied contents to your clipboard!